Clinical Trial Update: The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating daratumumab for monoclonal gammopathy of renal significance (MGRS) in Finland; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Kidney Failure
• Monoclonal Gammopathy of Renal Significance

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Helsinki University Central Hospital | Conditions: Kidney Failure, Paraproteinemias | Phase 2 | Status: RECRUITING